ASR Vermogensbeheer’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.41M Buy
15,098
+6,343
+72% +$4.32M 0.1% 199
2026
Q1
$6.76M Buy
8,755
+1,918
+28% +$1.47M 0.08% 213
2025
Q4
$5.28M Sell
6,837
-80
-1% -$54.3K 0.06% 248
2025
Q3
$3.89M Sell
6,917
-2,435
-26% -$1.38M 0.05% 290
2025
Q2
$4.91M Sell
9,352
-133
-1% -$74.2K 0.06% 259
2025
Q1
$6.02M Buy
+9,485
New +$6.52M 0.09% 204

Other funds holding REGN

ASR Vermogensbeheer's REGN Position: Q2 2026 in Review

ASR Vermogensbeheer increased its Regeneron Pharmaceuticals (REGN) stake by 72% in Q2 2026, buying an estimated $4.32M and bringing the position to 15,098 shares worth $9.41M. The position accounts for 0.1% of the portfolio, ranked #199.

ASR Vermogensbeheer first reported a position in REGN in Q1 2025 and has held it in 6 quarters since. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • ASR Vermogensbeheer held 15,098 shares of Regeneron Pharmaceuticals worth $9.41M as of Q2 2026.
  • ASR Vermogensbeheer bought 6,343 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $4.32M.
  • Regeneron Pharmaceuticals made up 0.1% of ASR Vermogensbeheer's portfolio in Q2 2026, its #199 holding.
  • ASR Vermogensbeheer first reported a position in Regeneron Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on ASR Vermogensbeheer's 13F filing for Q2 2026, filed 20 Jul 2026.